

HORIZONTE 2020:

OPORTUNIDADES DE FINANCIACIÓN EUROPEA DE I+D+I 2014-2020

SALUD, CAMBIO DEMOGRÁFICO Y BIENESTAR

IMI - INICIATIVA DE MEDICAMENTOS INNOVADORES



Marta Gómez Quintanilla
Representante española Salud e IMI
marta.gomez[at]cdti.es

<http://bit.ly/1nj1ToZ> 
[@EsHorizonte2020](https://twitter.com/Eshorizonte2020) 

Barcelona, 16 de marzo de 2016

El Programa Marco de la UE para
Investigación e Innovación

Parte esencial de la Estrategia
Europa 2020

2014-2020

Foco en retos sociales a los que se
enfrenta la sociedad UE, e.g. salud

77.028 M€

Simplificación

Partenariados:
Público-Privado, Público-Público

Cooperación Internacional



HORIZON 2020

Horizonte 2020 – Objetivos y estructura

Prioridades Europa 2020

Cooperación Internacional

Espacio Europeo de Investigación

Objetivos y principios compartidos

Difundir y ampliar participación
Ciencia con y para la sociedad

Abordando los
Retos Sociales

Creando Liderazgo
Industrial y Marcos
Competitivos

EIT

CCI


Excelencia en la Ciencia
Base

Acceso simplificado


*Reglas comunes, kit de esquemas de
financiación*

*Coherente con otras
acciones de la UE y los
EEMM*

Implementación



Implementación



Portal del participante

<http://ec.europa.eu/research/participants/portal/desktop/en/home.html>



RESEARCH & INNOVATION

Participant Portal

European Commission > Research & Innovation > Participant Portal > Home

HOMEFUNDING OPPORTUNITIESHOW TO PARTICIPATEEXPERTSSUPPORT

LOGINREGISTER



Horizon 2020 Funding

Starting from 1/1/2014

On this site you can find and secure **funding** for research & innovation projects under the following EU programmes:

- **2014-2020** Horizon 2020 - research and innovation framework programme
- **2007-2013** 7th research framework programme (FP7) and Competitiveness & Innovation Programme (CIP)

Non-registered users

- search for funding
- read the funding guide & download the legal documents
- check if an organisation is already registered
- contact our support services or check our FAQs

Registered users

- submit your proposal
- sign the grant
- manage your project throughout its lifecycle



WHAT'S NEW?



FUNDING OPPORTUNITIES



HOW TO PARTICIPATE



WORK AS AN EXPERT




MY PERSONAL AREA



INFORMATION AND SUPPORT

NCP = facilitador


<http://eshorizonte2020.es/que-es-horizonte-2020/horizonte-2020-en-espana/puntos-nacionales-de-contacto>



NCPs SALUD

Carolina Carrasco (CDTI) - carolina.carrasco@cdti.es
Juan Riese (ISCIII) - jriese@eu-isciii.es

Implementación



Salud, cambio
demográfico y
bienestar (7.257)


Partenariados con:

- EEMM y PPAA
- Industria
- Otros


- Partenariados
 - Público-Privados (PPP/JTI)
 - Público-Públicos (P2P)
 - Otros: ERANET Cofund, ...

Innovative Medicines Initiative 2

<http://www.imi.europa.eu/content/imi-2>



Mejorar el proceso de elaboración de medicamentos mediante un apoyo más eficaz a la **cooperación en I+D** entre el mundo académico, las PYME y el sector biofarmacéutico, para que los pacientes dispongan de **medicamentos mejores y más seguros.**



Carlos Moedas
European Commissioner
Research, Science and Innovation

“This booklet presents a snapshot, not the complete picture. In fact no static publication can capture the real-time dynamism of IMI’s ambitious programme of activities, but it does highlight the real value of public-private partnership in such an important sector to EU citizens.”

¿Quién propone las prioridades científicas y participar en los proyectos contribuyendo?

In kind/cash contribution matched by IMI funding for public beneficiaries

> 1.425
M€

efpia



BILL & MELINDA
GATES foundation

JDRF IMPROVING
LIVES.
CURING
TYPE 1
DIABETES.

OTROS

>
213
M€

Cualquiera que quiera y pueda contribuir tanto a los objetivos de IMI como activamente en especie o en dinero.

EFPIA Members

abbvie

Almirall

AMGEN

astellas

AstraZeneca

Baxalta

Boehringer Ingelheim

Biogen

Boehringer Ingelheim

Bristol Myers Squibb

Celgene

Chiesi

Lilly

Genzyme

Novartis

Novartis

IPSEN

Johnson & Johnson

LEO

Novartis

Novartis

MERCK

MSD
Be well

NOVARTIS

Novo Nordisk

Pfizer

Roche

SANOFI

Servier

Shire

Takeda

UCB

Pharmaceuticals

Bristol Myers Squibb

Novartis

Eli Lilly

ESTEVE

ORION PHARMA

Otsuka

RECORDATI

The Medicines Company

Vifor Pharma

EFPIA partners in research



EFPIA Associations

 AUTRIA Federation der Chemischen Industrie Österreichs (FCIO)	 BELGIUM pharma.be (Association Générale des Industriels du Médicament)	 DENMARK Lægemiddelindustriforeningen The Danish Association of the Pharmaceutical Industry (Læif)	 GERMANY Association of the Pharmaceutical Manufacturers in Germany (AIFA)	 CROATIA IF - Inovativna Farmaceutička Industrija	 CYPRUS Cyprus Cyprus Association of Pharmaceutical Companies (KEFΕΑ)
 FINLAND Lääketeollisuus ry (Pharma Industry Finland) (LIF)	 FRANCE Les Entreprises du Médicament (LEMD)	 IRELAND VfA (The Federation of Pharmaceutical Associations)	 ITALY Associazione Nazionale Farmaceutici (ANF)	 NETHERLANDS Association of Pharmaceutical Manufacturers in the Netherlands (APV)	 HUNGARY Association of Innovative Pharmaceutical Manufacturers (GPIH)
 GREECE Hellenic Association of Pharmaceutical Companies (ΣΦΕΕ)	 IRELAND Irish Pharmaceutical Industries Association (IPHA)	 ISRAEL Association of the Pharmaceutical Industry in Israel (FARMINDUSTRIA)	 ITALY Association of International Pharmaceutical Manufacturers (Siffa)	 IRELAND The Innovative Pharmaceutical Industry Association (IPHA)	 NETHERLANDS Netherlands Pharmaceutical Manufacturers Association (NPMA)
 LITHUANIA AND Venturing Innovative Companies Lithuania (Lithuania)	 LITHUANIA Lithuanian Pharmaceutical Manufacturers Association (LMI)	 NETHERLANDS Employees Union of Innovative Pharmaceutical Companies (INFARMA)	 NETHERLANDS Association of International Pharmaceutical Manufacturers (ARPIM)	 NETHERLANDS The Innovative Pharmaceutical Industry Association (IPHA)	 NETHERLANDS Association of Innovative Pharmaceutical Manufacturers (AIFP)
 NETHERLANDS opiforma (Association of Pharmaceutical Manufacturers in the Netherlands)	 NETHERLANDS Association of International Pharmaceutical Manufacturers (AIPM)	 NETHERLANDS Farmaindustria (Association of Pharmaceutical Manufacturers in the Netherlands)	 NETHERLANDS Association of International Pharmaceutical Manufacturers (ARPIM)	 NETHERLANDS Association of Pharmaceutical Research and Development (APRaD)	
 NETHERLANDS Lithuanian Pharmaceutical Manufacturers Association (LIF)	 NETHERLANDS Scientific Industries (Association of Pharmaceutical Manufacturers in the Netherlands)	 NETHERLANDS Association of International Pharmaceutical Manufacturers (AIFD)			
 NETHERLANDS The Association of the British Pharmaceutical Industry (ABPI)					

farmaindustria

Elegibilidad para recibir financiación



- Academic institutions
- Non-profit organizations
- Small & medium-size enterprises
- **Mid-sized enterprises (≤ 500 M€)**
- Non-profit patient organizations
- Non-profit public bodies
- International European interest organizations

Subvención: 100% Costes Directos + 25% Costes Indirectos

NO ser parte del consorcio que define el topic

Futuras convocatorias: Conv. 9

<http://www.imi.europa.eu/content/future-topics>



Call topics:

- Topic 1:** Addressing the clinical burden of **Clostridium difficile infection** (CDI): Evaluation of the burden, current practices and set up of a European Research Platform (RIA)
- Topic 2:** Development Of Immune Tolerance Therapies For The Treatment of **Rheumatic Diseases** (RIA)
- Topic 3:** **Data Quality** in preclinical research and development (RIA)
- Topic 4:** Next Generation of **Electronic Translational Safety** – NexGETS (RIA)
- Topic 5:** Identification and Validation of Non-invasive Markers across the Spectrum of **Nonalcoholic Fatty Liver Disease** (NAFLD) (RIA)
- Topic 6:** Joint **Influenza Vaccine** Effectiveness Surveillance (JIVES) (RIA)

Previsión apertura:

6 de abril 2016

BORRADOR

Futuros *topics* y programas en marcha

ND4BB

New Drugs for Bad Bugs
Resistencia
Antimicrobiana

RADAR

Remote Assessment of Disease and
Relapse

ÉBOLA

& other filovirus

BD4BO

Big Data for
Better Outcomes

IMI Call for proposals to explore new scientific opportunities in ongoing IMI JU collaborative projects

<http://www.imi.europa.eu/content/new-opportunities>

Convocatorias proyectos en marcha:

- **EU LEAD FACTORY:** www.europeanleadfactory.eu las oportunidades abiertas www.europeanleadfactory.eu/proposals
- **ENABLE-** European Gram Negative AntiBacterial Engine: Pueden encontrar a continuación información sobre el proyecto (<http://nd4bb-enable.eu>) y las oportunidades abiertas (<http://nd4bb-enable.eu/open-calls>).

IMI Stakeholder Forum 2015

www.imi.europa.eu/events/2015/03/13/imi-stakeholder-forum-2015

IMI Stakeholder Forum 2015

Agenda

15.06.2015 • Crowne Plaza Le Palace
Brussels • Belgium

10:30 – 11:00 *Registration & welcome coffee*

11:00 **Welcome**

Rudolph Strohmeier

Deputy Director-General responsible for research programmes, Directorate-General for Research and Innovation, European Commission
Deputy Chair of the IMI Governing Board

15:45 – 17:00 Session 3 | Where are we going? The next big things in biomedical R&D

15:45 – 15:50 Introduction by Irene Norstedt

15:50 – 17:00 Parallel tracks

Session A | Advanced therapies: from treatment to cure & prevention

Moderator: Arnd Hoeveler

Head of unit, novel medical developments, DG Research & Innovation, European Commission

Session B | Enabling technologies: better health outcomes through big data

Moderator: Stavros Malas

IMI States Representatives Group member; Group Head, Institute of Neurology and Genetics, Cyprus

Session C | Optimising IMI's funding schemes

Moderator: Marta Gómez Quintanilla

Chair of the IMI States Representatives Group, Ministry of Economy and Competitiveness, Spain

Session A | Advanced therapies: from treatment to cure & prevention

Session B | Enabling technologies: better health outcomes through big data

14:00 – 15:20 Session 2 | IMI2: Where are we now?

14:00 – 14:20 Philippe De Backer MEP

14:20 – 14:40 IMI2: objectives and outlook

Giulia Del Brenna, Deputy Head of Cabinet, Cabinet of Commissioner Carlos Moedas
Magda Chlebus, Director Science Policy, EFPIA

14:40 – 15:30 Panel discussion

Moderator: Adam Smith, Chief Scientific Officer, Nobel Media

Sanjoy Dutta, Assistant Vice President, Translational Development & International Partnerships, JDRF

Donata Medaglini, Associate Professor of Microbiology, University of Siena
IMI VSV-EBOVAC and FLUCOP projects

Maria Dolores Navarro Rubio, President of the Spanish Patients Forum, Member of the IMI Scientific Committee Member

Corinne De Vries, Risk Management Specialist, Scientific & Regulatory Management, European Medicines Agency (EMA)

15:30 – 15:45 *Coffee break*

Panellists

- Tim Allsopp
Neusentis Regenerative Medicine, Pfizer, Coordinator of IMI EBISC Project
- Lucia Faccio
Head of Business Development
Fondazione Telethon
- Samantha Parker
Chief Patient Affairs Health Policies Officer, LYSOGENE
- Rocio Salvador Roldan
Policy Officer, Medicinal products - authorisations, European Medicines Agency, Directorate General for Health and Food Safety
European Commission

Consideration to further develop the programme.

Panellists

- Terje Peetso
Digital Society, Trust and Security, Health and Well-Being, Directorate General for Communications Networks, Content and Technology, European Commission
- Nina Lathia
Senior Technical Advisor – Observational Data Unit, National Institute for Health and Care Excellence (NICE)
- Jérôme Boehm
Policy Officer – Team Leader e-Health and Health Technology Assessment
Directorate General for Health and Food Safety
European Commission

Panellists

- Magali Poinot
Legal Manager, IMI
- Magda Gunn
Scientific Project Manager, IMI
- Catherine Brett
External Relations Manager, IMI
- Mila Kivipelto
Center for Alzheimer Research and Aging Research Center
Karolinska Institutet
IMI EPAD project

17:00 – 18:00 Closing session

17:00 – 17:30 Feedback from rapporteurs of parallel sessions

17:30 – 18:00 Summary and conclusions by **Anders Olauson**, President of the European Patient Forum

18:00 End of the event

IMI2 –EFPIA Idea generation website

<http://imi.efpia.eu/imi2/imi2-idea-generation>

Innovative Medicines Initiative

efpia*

Home

About IMI

Achievements

IMI2

Media Room

Resources

Contact

Search...

IMI2 idea generation

ABOUT YOU

YOUR PROPOSAL

Scientific question/topic for IMI2*

Rationale - problem statement *

Expected deliverables and impact *

I plan to address your scientific question/project?*

RELEVANCE TO THE STRATEGIC RESEARCH AGENDA

Therapeutic areas covered by the SRA

Enablers for each theme

RELEVANCE TO IMI2 COLLABORATIVE SCHEME

Why is IMI2 an ideal place to address your scientific question/project?

[Home](#) / [IMI2](#) / IMI2 idea generation

IMI2 idea generation



División
Programas de la UE

IMI2 –Desarrollo de topics y generación ideas

<http://imi.efpia.eu/imi2/create-your-imi2>

Create your IMI2

Innovative Medicines Initiative2: Idea generation and development of Call topics

Strategic Research Agenda (SRA): The right prevention and treatment, to the right patient at the right time

Who will translate the SRA into projects?

Can third parties submit a proposal?


Can the proposer be part of the IMI consortium?

Is there a template?

When to submit an idea?

What happens after submission?

Need more information?



Conclusiones



- **Estrategia.** Imprescindible para resultados de impacto
- La **preparación** es esencial para el éxito de las propuestas
- Escenario altamente competitivo-> **hay que ser excelente**
- **Profesionalización en la gestión**
 - Grandes proyectos (20+)
 - Visión estratégica y de conjunto
 - Coordinación e influencia a nivel de entidad

Contad con nuestra ayuda



Contactos «Salud»:


Carolina Carrasco

[Carolina.carrasco\[at\]cdti.es](mailto:Carolina.carrasco[at]cdti.es)

Marta Gómez Quintanilla

[Marta.gomez\[at\]cdti.es](mailto:Marta.gomez[at]cdti.es)

☎ 915815562



Reflexión final

**Opportunity rarely knocks on your door.
Knock rather on opportunity's door if you
ardently wish to enter.**

B. C. Forbes



Bertie Charles Forbes (May 14, 1880 – May 6, 1954) was a Scottish financial journalist and author who founded Forbes Magazine.



CONTACTO:

Marta Gómez Quintanilla

Spanish Representative - HEALTH

Spanish Representative - IMI

Spanish MB Member - JPND

☎ 34 91 581 55 62 / 00

[marta.gomez\[at\]cdti.es](mailto:marta.gomez[at]cdti.es) - www.cdti.es

✉ <http://bit.ly/1nj1ToZ>

🐦 @EsHorizonte2020
@EU_RDI_LifeSci

Info H2020: Web, guía y twitter españoles

Ciencia Excelente | Liderazgo Industrial | Retos Sociales | Más Europa

Google® Búsqueda por



ESHORIZONTE2020
Portal español del Programa Marco de Investigación e Innovación de la Unión Europea



@EsHorizonte2020

www.guiah2020.es

Horizonte 2020 = investigación e innovación

HORIZONTE 2020	HOW TO PARTICIPATE	ACTUALIDAD	EVENTO
¿Qué es? Es el programa que financia proyectos de investigación e innovación de diversas áreas temáticas en el contexto europeo, contando con casi 80.000ME para el periodo 2014-2020. Investigadores, empresas, centros tecnológicos y entidades públicas tienen cabida en este programa. Amplie la información aquí.	Cómo Participar La Guía del Participante en Horizonte 2020 le permitirá tener información general de H2020 y sobre el proceso de participación. Para obtener asesoramiento personalizado, los Puntos Nacionales de Contacto temáticos le ayudarán en todas las fases de la propuesta. Acceda a la sección Cómo participar	Lanzamiento oficial de los programas de trabajo 2016-2017 de Horizonte 2020 La Comisión Europea impulsará la competitividad invirtiendo casi 16 000 millones EUR en actividades de investigación e innovación en los próximos dos años en el marco de Horizonte 2020. Más información	Curso de Especialización de Gestores en Bruselas Este programa da apoyo financiero a la estancia temporal en la oficina del CDTI en Bruselas, la oficina SOST, a través de un concurso de méritos. La estancia tiene una duración de 8 semanas. Más información

CALENDARIO DE ACTIVIDADES

Octubre 2015

L	M	X	J	V	S	D
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31	

Puntos Nacionales DE CONTACTO

NOTICIAS

www.eshorizonte2020.es

H2020 Guía del participante Horizonte 2020

INICIO | GUÍA RÁPIDA | 1ª PARTE | 2ª PARTE | 3ª PARTE | ANEXOS | DESCARGAS

H2020

Horizonte 2020: El Programa Marco de Investigación e Innovación

Acerca de esta guía

HABLAMOS EN

Resumen apoyo CE: helpdesk y guías de interés

H2020

- Horizon 2020 Helpdesk <http://ec.europa.eu/research/index.cfm?pg=enquiries>
- H2020 manual <https://ec.europa.eu/research/participants/portal/desktop/en/funding/guide.html>

IPRs

- IPR Helpdesk: Assistance on Intellectual Property issues
www.iprhelphdesk.eu

Ética

- Ethics: from proposal definition to project implementation
http://ec.europa.eu/research/participants/docs/h2020-funding-guide/cross-cutting-issues/ethics_en.htm

Sexo & Género

- Guidance on methods of sex / gender analysis and the issues to be taken into account http://ec.europa.eu/research/science-society/gendered-innovations/index_en.cfm
- Fact sheet: Gender Equality in Horizon 2020
https://ec.europa.eu/programmes/horizon2020/sites/horizon2020/files/FactSheet_Gender_091213_final.pdf

Ensayos clínicos

- Template for essential information to be provided for proposals including clinical trials / studies / investigations
http://ec.europa.eu/research/participants/portal/doc/call/h2020/sc1-pm-11-2016-2017/1677602-essential_information_for_clinical_studies_en.pdf
- Clinical Studies in H2020 Proposals (PPT infoday)
http://ec.europa.eu/research/health/pdf/infoday_2015/clinical_studies_in_h2020.pdf

Comunicación

- Guía: http://ec.europa.eu/research/participants/data/ref/h2020/other/gm/h2020-guide-comm_en.pdf

Difusión

- Guía Open acces:
http://ec.europa.eu/research/participants/data/ref/h2020/grants_manual/hi/oa_pilot/h2020-hi-oa-pilot-guide_en.pdf

Apoyo CDTI en todas las fases ► NCPs

¡NO EXCLUSIVO!

- Oficinas apoyo entidad/local/regional
- Apoyo aspectos concretos EU: socios, IPRs, etc.



Apoyo CDTI en todas las fases



- **APCs:** ayuda a la preparación de propuestas comunitarias (empresas) <http://bit.ly/1i2DsHv>
- **Programa de Especialización de Gestores:** estancias de gestores en nuestra oficina SOST – Programa formación + plan de trabajo en Bruselas <http://bit.ly/1iuOHHQ>
- **Oficinas apoyo:** contratación de servicios a entidades especializadas en el apoyo a empresas para su participación en el Horizonte 2020 <http://bit.ly/1g1vzOn>
- **Red PIDI:** Servicio de Información y Asesoramiento Telemático de la Red de Puntos de Información sobre Actividades de Investigación, Desarrollo e Innovación (PI+D+i) → nodo especializado en programas internacionales para la financiación de proyectos de I+D. <http://bit.ly/1gh3w1B>

¿Donde hay más información?



http://ec.europa.eu/research/horizon2020/index_en.cfm



<http://www.eshorizonte2020.es/>



<http://ec.europa.eu/research/participants/portal>



http://ec.europa.eu/research/health/index_en.html



http://ec.europa.eu/dgs/health_consumer/index_en.htm



http://ec.europa.eu/health/index_en.htm



<https://webgate.ec.europa.eu/eipaha>



<http://ec.europa.eu/digital-agenda/en/eHealth%20>



http://ec.europa.eu/europe2020/index_es.htm



http://ec.europa.eu/research/innovation-union/index_en.cfm



www.iprhelpdesk.eu



www.imi.europa.eu

GLOSSARY & LINKS

- **AAL:** Ambient Assisted Living www.aal-europe.eu /Active and Assisted Living
- **COCIR:** European Coordination Committee of the Radiological, Electromedical and Healthcare IT Industry www.cocir.org
- **EC:** European Commission <http://ec.europa.eu>
- **EDCTP:** The European and Developing Countries Clinical Trials Partnership www.edctp.org
- **EJP:** European Joint Programme
<http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/other/index.html>
- **EFPIA:** The European Federation of Pharmaceutical Industries and Associations www.efpia.eu
- **EIP:** European Innovation Partnership http://ec.europa.eu/research/innovation-union/index_en.cfm?pg=eip
- **EIT:** European Institute of Innovation & Technology <http://eit.europa.eu>
- **EMPIR:** European Metrology Programme for Innovation and Research www.emrponline.eu
- **FET:** Future and Emerging Technologies
- **HBP:** Human Brain Project www.humanbrainproject.eu
- **IMI:** Innovative Medicines Initiative www.imi.europa.eu
- **JPI AMR:** Joint Programming in Antimicrobial Resistance www.jpiamr.eu
- **JPI HD&HL:** A Healthy diet for a healthy life www.healthydietforhealthylife.eu
- **JPI MYBL:** Joint Programming More Years, Better Lives www.jp-demographic.eu
- **JPI:** Joint Programming Initiative http://ec.europa.eu/research/era/areas/programming/joint_programming_en.htm
- **JPND:** Joint Programming in Neurodegenerative Research www.neurodegenerationresearch.eu
- **KIC:** Knowledge and Innovation Community <http://eit.europa.eu/kics> / **HL&AA:** Healthy Living and Active Ageing
- **PPP:** Public-Private Partnership & **P2P:** Public-Public Partnership
http://ec.europa.eu/research/era/partnership/partnering_en.htm
- **SBIR:** Small Business Innovation Research www.sbir.gov
- **SIA:** Strategic Implementation Agenda / **SIP:** Strategic Implementation Plan
- **SME:** Small and medium-sized enterprises http://ec.europa.eu/enterprise/policies/sme/index_en.htm